Clinical Trial

Short-Term Safety of Low-Dose Creatine Hydrochloride: A 28-Day Single-Arm Pilot Study

Completed
View on ClinicalTrials.gov →
Summary
Background: Creatine monohydrate (typically 5-20 g/day) has a well-established safety profile across diverse populations. Creatine hydrochloride (CR-HCl) is a highly soluble creatine formulation that may allow effective supplementation at substantially lower doses (750 mg - 3 g/day); however, controlled human safety data specific to CR-HCl remain limited. Objective: To evaluate the short-term laboratory safety and tolerability of low-dose CR-HCl supplementation administered for 28 days in healthy adults.
Trial Details
NCT Number NCT07521059
Lead Sponsor Vireo Systems, Inc.
Conditions Safety of Short Term Creatine Hydrochloride Dosing
Enrollment 11 participants
Start Date 2024-05-30
Primary Completion 2024-07-03 (estimated)
Study Completion 2024-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-09